2-[(6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylbenzene-1,4-diol | 1254162-65-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-[(6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylbenzene-1,4-diol
• CAS: 1254162-65-6
• 化学式: C₂₉H₄₆O₃
• 分子量: 442.682
• InChiKey: PIZFWXYPKRFPFP-KTWAZNHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  32
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylbenzene-1,4-diol 在 iron(III) chloride hexahydrate 作用下， 以 醋酸异丙酯 、 水 、 异丙醇 为溶剂， 以99 %的产率得到α-tocotrienol quinone
  参考文献：
  名称：

  [EN] METHODS FOR SYNTHESIS OF RACEMIC, SCALEMIC, AND CHIRAL ALPHA-TOCOTRIENOL QUINONE
  [FR] MÉTHODES DE SYNTHÈSE D'ALPHA-TOCOTRIÉNOL QUINONE RACÉMIQUE, SCALÉMIQUE ET CHIRALE

  摘要：

  The application discloses methods useful for the synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone, including synthetic intermediates and methods for making said synthetic intermediates.

  公开号：

  WO2023009610A1
• 作为产物：
  描述：

  2,2'-((2,3,5,6-tetramethyl-1,4-phenylen)bis(oxy))bis(tetrahydro-2H-pyran) 在 正丁基锂 作用下， 以 正庚烷 、 醋酸异丙酯 、 异丙醇 为溶剂， 反应 5.0h， 生成 2-[(6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylbenzene-1,4-diol
  参考文献：
  名称：

  [EN] METHODS FOR SYNTHESIS OF RACEMIC, SCALEMIC, AND CHIRAL ALPHA-TOCOTRIENOL QUINONE
  [FR] MÉTHODES DE SYNTHÈSE D'ALPHA-TOCOTRIÉNOL QUINONE RACÉMIQUE, SCALÉMIQUE ET CHIRALE

  摘要：

  The application discloses methods useful for the synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone, including synthetic intermediates and methods for making said synthetic intermediates.

  公开号：

  WO2023009610A1

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LA PRÉVENTION ET/OU LE TRAITEMENT D'UNE MALADIE MITOCHONDRIALE, NOTAMMENT L'ATAXIE DE FRIEDREICH
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2021202986A1

  公开（公告）日：2021-10-07

  The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

  该披露提供了治疗化合物、组合物（例如治疗剂或药物）和方法，用于预防或治疗哺乳动物主体中的线粒体疾病，如弗里德赖希共济失调，减少与线粒体疾病（例如弗里德赖希共济失调）相关的风险因素、症状和/或症状，并/或减少线粒体疾病（例如弗里德赖希共济失调）的发生可能性或严重程度。该披露还提供了用于生产上述治疗组合物的新型中间体。在某些情况下，这些中间体本身可能是治疗剂或治疗剂的前药（例如治疗化合物的还原形式）。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS POUR LA PRÉVENTION ET/OU LE TRAITEMENT DE DIVERSES MALADIES OU TROUBLES MITOCHONDRIAUX, NOTAMMENT LA MALADIE DE FRIEDREICH
  申请人：STEALTH BIOTHERAPEUTICS INC

  公开号：WO2022261347A1

  公开（公告）日：2022-12-15

  The disclosure provides various new and existing compounds for use alone or as formulated in a composition (e.g., medicaments) and related methods and uses for treating, preventing, inhibiting, ameliorating or delaying the onset of a disease, disorder or condition associated with ferroptosis in a mammalian subject. Such ferroptosis related diseases, disorders or conditions can include: Friedreich's ataxia, Leigh syndrome, Leber's Hereditary Optic Neuropathy (LHON), (proliferative, non-proliferative, diabetic or hypertensive) retinopathy, refractory epilepsy, Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), Amyotrophic Lateral Sclerosis (ALS), ischemic stroke, a cardiomyopathy (e.g. cardiac ischemia-reperfusion injury, myocardial infarction, Barth cardiomyopathy, hypertrophic cardiomyopathy or heart failure), renal injury, renal ischemia reperfusion injury or acute renal failure.

  该披露提供了各种新的和现有的化合物，可单独使用或作为组合物（例如药物）中的成分，并提供了用于治疗、预防、抑制、改善或延迟哺乳动物主体中与铁死亡相关的疾病、疾病或疾病的发作的相关方法和用途。这种与铁死亡相关的疾病、疾病或疾病可以包括：弗里德雷希共济失调、利氏综合征、勒伯遗传性视神经病变（LHON）、（增殖性、非增殖性、糖尿病或高血压）视网膜病变、难治性癫痫、帕金森病（PD）、阿尔茨海默病（AD）、亨廷顿病（HD）、肌萎缩性侧索硬化症（ALS）、缺血性中风、心肌病（例如心脏缺血再灌注损伤、心肌梗塞、巴斯心肌病、肥厚型心肌病或心力衰竭）、肾损伤、肾缺血再灌注损伤或急性肾衰竭。
• TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
  申请人：PTC Therapeutics, Inc.

  公开号：EP3827815A1

  公开（公告）日：2021-06-02

  Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

  治疗或抑制广泛性发育障碍（PDDs）的方法，包括自闭症、阿斯伯格综合症、儿童分裂症（CDD）、雷特氏症、未另作指定的发育障碍（PDD-NOS）或注意缺陷/多动障碍（ADHD），包括向有需要的受试者施用治疗有效量的一种或多种本文公开的化合物。
• Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
  申请人：BioElectron Technology Corporation

  公开号：US10195161B2

  公开（公告）日：2019-02-05

  The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

  本发明涉及用生育三烯酚醌（包括α-生育三烯酚醌）治疗勒伯遗传性视神经病变和显性视神经萎缩的方法，以减轻该疾病的症状。
• Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
  申请人：Miller Guy M.

  公开号：US11021424B2

  公开（公告）日：2021-06-01

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

  本发明公开了治疗或抑制线粒体疾病的方法，如弗里德雷希共济失调（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或卡恩斯-赛尔综合征（KSS），以及用于本发明方法的化合物，如α-生育酚醌。本发明还公开了用于治疗其他疾病的方法和化合物。本发明还公开了用于评估受试者代谢状态和治疗效果的能量生物标志物。还公开了调节、正常化或增强能量生物标志物的方法，以及用于此类方法的化合物。